NEWS
SFC Capital Puts £387,865 on Nayara’s Between-Visit AI
SFC Capital led a £387,865 pre-seed for Nayara, whose WhatsApp cancer companion is now sold as hospital kit for care between visits.
GY Health Technology Limited, which trades as Nayara, closed a £387,865 pre-seed round led by SFC Capital on 5 November 2026. The London firm sells AI companions that answer patients between clinic visits and pass urgent concerns to clinical teams.
SFC Capital is a high-volume UK seed shop, not a specialist cancer fund. The bet is that a WhatsApp guide built for breast cancer can be sold as hospital kit for the long stretch of care that never happens in a ward.
SFC Capital Leads a £387,865 Pre-Seed for Nayara
UK deal records list the close at £387,865. Nayara’s own announcement did not put a figure on the round, and named SFC Capital as lead rather than as the only cheque. Adam Beveridge, a fund principal at SFC Capital, said the firm was backing a team that could help both patients and providers as health systems run hot.
THE DEAL AT A GLANCE
- The round: £387,865 pre-seed, listed on 5 November 2026, led by SFC Capital.
- The pitch: AI companions for hospitals, health systems and medical technology companies.
- The first product: a breast cancer companion the company says has already supported hundreds of patients.
- The spend: product work, clinical validation and commercial expansion.
SFC Capital wrote that PitchBook Data counted 106 investments in 2025, 38 more than Haatch and 63 more than Fuel. Its pre-seed model is built around the Seed Enterprise Investment Scheme, which caps how much a company can raise under that wrapper at £250,000. A listed round of £387,865 sits £137,865 above that cap, so the close reads as a led round with other British money in it, not as one SEIS ticket.
Each SFC SEIS tranche typically holds around 15 to 20 companies. Nayara is one more name in that spread, in a book the firm itself counts at 41 medtech holdings.
Betty Answers on WhatsApp Between Appointments
The product patients already see is Betty, the breast cancer companion. Nayara calls her the first “clinical-grade” breast cancer guide built by its community. There is no hospital login. A patient starts on a text or a WhatsApp message and is asked where she sits on the path, from a new diagnosis through surgery, chemotherapy and recovery.
The showcase page says Betty is HIPAA-aligned and that a user can wipe her data by typing “delete my data.” It also prints a standard warning that the site is not medical advice. Those two lines sit on the same product.
WHAT BETTY’S PAGE SAYS SHE HANDLES
- Emotional support: 24/7 companionship, hard talks with family, anxiety, fear, and questions about relationships and intimacy.
- Physical support: treatment options, side effects, symptom tracking, pre- and post-treatment checklists, and appointment planning.
- Logistics: nearby counsellors, financial-aid programmes, insurance and benefits, legal options, and community groups.
The same page displays scores of 4/5 for “feel supported” and 4.5/5 NPS, plus short notes attributed to first names and ages. Those are marketing figures, not a published trial. In its own FAQ, Nayara says Betty does not replace a medical team and is there to keep people informed and prepared between appointments.
In February 2026, co-founder and chief executive Gal Moore wrote that the company had put patient-facing companions with 300 people alongside clinicians at University College London Hospitals and the George Washington Cancer Center. The 5 November 2026 announcement used the looser word hundreds for the same oncology work. Neither hospital has published its own account of the deployment.
A Company Number, an Oxford Office, One Director
The operating name is Nayara. The legal name on the GY Health Technology Limited company file is thinner. Companies House records company 15899737 as a private limited firm incorporated on 15 August 2024, with SIC code 71122, engineering-related scientific and technical consulting. Last accounts were made up to 31 August 2025.
The website still prints Gravita Aldgate Tower, 2 Leman Street, London E1 8FA. The register now points at Gravita Oxford LLP, First Floor, Park Central 40-41, Park End Street, Oxford OX1 1JD, after a change on 27 July 2026.
DATES ON THE REGISTER
- 15 August 2024: Incorporates as GY Health Technology Limited. Gal Samuel Moore, a British director born in January 1983, is appointed the same day.
- 20 November 2024: HSBC Innovation Banking takes a charge over the company.
- 1 July 2025: Yael Kfir ceases to be a person with significant control.
- 8 September 2025: Kfir’s appointment as director ends, leaving Moore as the only active director on the file.
- 23 June 2026: The HSBC charge is marked satisfied.
- 21 August 2026: Members pass resolutions to allot securities, adopt new articles and drop pre-emption rights.
- 14 October 2026: A further allotment takes share capital to £123.4343.
- 5 November 2026: The company announces the SFC Capital-led pre-seed.
Nayara’s site names Rami Kahan as co-founder and chief commercial officer. He does not appear as a director on the public file. The team page lists seven people on the operating side: Moore, Kahan, Anna Roitberg as AI engineer, Eduard Rudyk as vice president of research and development, Noa Hirsch as vice president of clinical, Guy Mizrachi as head of product and David Belfer as head of business development. Advisers named there include oncologist Dr. Yardenna Dolev and behavioural psychologist Dr. Noga Diamant.
Why Hospitals Buy a Companion They Do Not Speak To
Nayara’s paying customer is not the woman on WhatsApp. The announcement pitches hospitals, health systems and medical technology companies. The companion answers routine questions, sends check-ins, and routes anything that looks like a warning to a human team. The sale is fewer repetitive calls and a clearer view of patients who are not in the building.
The company says only around 90% of healthcare happens outside hospital, with 10% inside. That split is its own framing, not an NHS statistic. It is also the commercial point. A clinic already owns the appointment. The inbox between appointments is what it cannot staff.
We started Nayara with a simple belief: no patient should feel alone in their healthcare journey. No warning sign should go unaddressed because the clinical team lacked the information, or the time, to act.
Gal Moore, co-founder and chief executive, Nayara announcement, 5 November 2026
On the enterprise side, Nayara says it will map the end-to-end patient journey with a buyer’s clinical team, then set knowledge, boundaries and escalation rules, then design check-ins and tone. Moore has described the next product as a platform for oncology, fertility, chronic disease, remote monitoring and post-surgical recovery, not only breast cancer. That is the jump the new money is meant to fund: from one named companion to a kit other pathways can copy.
What Makes a Patient Chatbot a Medical Device?
The raise is earmarked in part for clinical validation, which is the honest tell. A bot that only books a slot is usually an admin tool. A bot that tracks symptoms, talks through treatment and flags risk sits closer to software the Medicines and Healthcare products Regulatory Agency treats as a device.
The MHRA’s test is intended purpose. If the manufacturer’s claims point at diagnosis, prevention, monitoring or treatment, the product can fall under medical-device law. Promotional pages count. A footer that says the site is not medical advice does not, on the agency’s own wording, cancel medical claims made above it.
HOW UK DEVICE LAW TREATS HEALTH SOFTWARE
| What the software does | How the MHRA frames it |
|---|---|
| Books appointments, stores a file, or passes messages with no clinical interpretation | Unlikely to be a device if the job stays administrative |
| Calculates a dose, offers a diagnosis or prognosis, or steers treatment | Likely to be a device |
| Interprets data a clinician never reviews in raw form | May qualify as a device |
| Prints “for information only” while the rest of the site makes medical claims | The disclaimer does not decide the status on its own |
Betty’s public page offers symptom tracking, side-effect help and treatment explanations, then denies that the site is medical advice. That mix is exactly why a pre-seed of this size is being spent on validation rather than on ads alone. On 6 October 2026 the government accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, a report published on 10 September 2026. The MHRA opened AI Airlock Phase 3 the same day, a sandbox aimed at watching AI devices after they ship. It said the first wave of innovators would be selected in November 2026, with draft guidance on managing changes to AI devices due by December 2026 and a full roadmap by Spring 2027.
Health Innovation Minister James Frith said patients should get AI that is safe, effective and overseen, and that innovation must not come at the expense of safety. Nayara has not said whether it has applied to Airlock, or whether Betty is on the UK device register.
WHAT WE KNOW
- The close: a listed £387,865 pre-seed led by SFC Capital on 5 November 2026.
- The live product: Betty, a WhatsApp and text companion for breast cancer, with hundreds of users claimed in the announcement.
- The legal shell: GY Health Technology Limited, 15899737, one active director, Oxford registered office.
WHAT IS UNCONFIRMED
- Device status: no public MHRA registration or Airlock place has been attached to Betty or the platform.
- Hospital contracts: UCLH and the George Washington Cancer Center appear in Moore’s February 2026 post, not in those hospitals’ own releases.
- The full cap table: SFC Capital is named as lead; other British participants are not listed in the announcement.
Until those three points land, “clinical-grade” remains a company phrase, not a regulator’s stamp.
Patient AI Is a Crowded Field for a Small Cheque
Tracxn, updated on 28 October 2026, counted 1,222 companies building AI agents for patient or clinical support, with 63 of them funded. Nayara’s listed round is a rounding error next to the larger cheques in that set. That is the shape of the wager, not a knock on the product. SFC Capital wins by writing many small UK tickets, then following the ones that get traction.
The job Nayara is selling, routine contact between visits, is not a private idea. Other health AI firms are raising for patient navigation, follow-up calls and inbox triage in the same window. A £387,865 close does not buy a category. It buys time to turn one companion into a platform other clinical teams can configure, and to put evidence under the claims already on the website.
Moore’s earlier line of work sits in data and robotics rather than in oncology practice. The clinical weight on the public team page sits with Hirsch as vice president of clinical and with named advisers in oncology, behavioural psychology and social work. For a hospital buyer, that split is the diligence question: is this a care product with engineers attached, or an AI product with clinicians on the masthead?
Nayara Will Spend the Round on Testing and Sales
The announcement is blunt about use of proceeds. The money is for product development, clinical validation and commercial expansion. In plain terms, that is more pathway templates, evidence a buyer’s safety committee will accept, and a sales motion aimed at hospitals and device makers rather than at founding-member patients on WhatsApp.
We see tremendous potential in Nayara’s vision and the team’s ability to execute. As healthcare systems face mounting pressure, solutions that can deliver meaningful improvements for both patients and providers represent an exciting investment opportunity. We’re delighted to support Nayara in its next stage of growth.
Adam Beveridge, fund principal, SFC Capital, 5 November 2026
SFC Capital can afford for this name to be one of 15 or 20 in a tranche. Nayara cannot. It has a live companion, a company file that is only a little more than two years from incorporation, and a product page that already talks like a medical service while denying that it is one. The £387,865 is the price of trying to make those three facts add up.
Frequently Asked Questions
What Is GY Health Technology Limited’s Company Number?
The company number is 15899737. It is a private limited company on the UK register, with SIC code 71122 for engineering-related scientific and technical consulting, and its last filed accounts were made up to 31 August 2025. The public file lists Gal Samuel Moore as the only active director.
How Much SEIS Tax Relief Can a UK Investor Claim?
Under the Seed Enterprise Investment Scheme, an individual can invest up to £200,000 a year and claim 50% income tax relief, with a possible carry-back to the previous tax year, if the shares are held for at least three years and the company stays eligible. A company itself may raise no more than £250,000 under SEIS, which is why a listed £387,865 round cannot be read as a pure SEIS raise.
Does Betty Replace a Doctor or a Nurse?
Nayara says no. Its product FAQ states that Betty complements medical care by helping patients stay informed and prepared between appointments, and that she can sit alongside other support services. Users are told they can delete their data at any time by typing “delete my data.”
What Is the MHRA AI Airlock?
AI Airlock is the MHRA’s regulatory sandbox for AI used as a medical device. Phase 3, opened on 6 October 2026 with three further years of government funding, is aimed at post-market surveillance, watching how AI tools behave after they are in use rather than only at the point of first approval. The agency said the first wave of Phase 3 innovators would be selected in November 2026.
Disclaimer: This article is news reporting and analysis for information only. It is not medical advice, a diagnosis, or a recommendation to use any patient app, and it is not investment, tax or legal advice, including on SEIS relief or on shares in early-stage companies. Anyone making a health decision should speak to a qualified clinician, and anyone considering an investment or tax position should speak to a regulated financial adviser and, where needed, a tax specialist. Figures, company statuses, product claims and regulatory positions reflect the sources cited and can change.
-
BUSINESS5 months agoAramco Crash Kills 14 Two Days After Oil Restart
-
NEWS6 months agoSalah Captained Egypt to Their First World Cup Win
-
GAMING2 months agoZelda’s 40th Switch 2 Ships Without a Zelda Game
-
NEWS3 months agoApple Labor Day Deals Hide June’s Memory Price Hike
-
NEWS4 months agoEl Niño Puts Israel’s Needed Winter Rain on a Flood Clock
-
GAMING2 months agoPalworld 1.0.4 Adds Palpedia Search After the 1.0 Launch
-
NEWS4 months agoSaudi Visa Routes Split Nigerian Travelers Into Two Speeds
-
BUSINESS9 months agoBAE’s 60-Year Saudi Franchise Now Runs Through Taif
